Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
Want to see LEGN full AI Analyst Report?
LEGN Stock Chart & Stats
$21.17
-$0.50(-1.49%)
At close: 4:00 PM EST
$21.17
-$0.50(-1.49%)
Day’s Range― - ―
52-Week Range$16.24 - $45.30
Previous CloseN/A
Volume249.07K
Average Volume (3M)3.03M
Market Cap
$5.33B
Enterprise Value$5.94B
Total Cash (Recent Filing)$834.63M
Total Debt (Recent Filing)$389.31M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Aug 18, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding193,439,790
10 Day Avg. Volume3,197,052
30 Day Avg. Volume3,031,679
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)4.00
Price to Sales (P/S)3.89
P/FCF Ratio-23.85
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue5.22
Enterprise Value/Gross Profit9.49
Enterprise Value/Ebitda-32.82
Forecast
1Y Price Target
$57.27Price Target Upside170.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)0.04
Revenue Forecast (FY)$1.43B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue ScalingLegend has demonstrated durable top-line scale driven by CARVYKTI, rising from ~69M (2021) to TTM ~$1.14B with a healthy gross margin near 54%. That steady revenue base supports reinvestment, commercial expansion and a credible path to sustained adjusted profitability as unit economics improve.
Manufacturing & Operational ReliabilityHigh manufacturing success and rapid turnaround materially reduce supply bottlenecks for a complex autologous therapy. Reliable execution enables broader earlier-line adoption, improves physician and center confidence, and underpins margin recovery and predictable revenue delivery as volumes grow.
Breakthrough In Vivo Platform Proof‑of‑ConceptEarly LB2501 in‑vivo results suggest the TaVec platform can generate CAR‑T in patients without ex‑vivo manufacturing or lymphodepletion. If confirmed, this structural innovation could broaden addressable markets, lower production complexity and costs, and create a durable competitive moat beyond current CAR‑T supply constraints.
Bears Say
Persistent Negative Cash FlowConsistent operating and free cash flow deficits mean the company is still funding growth through cash reserves or external capital. Continued cash burn risks diluting shareholders or constraining R&D and manufacturing investments if adjusted profitability targets slip or milestone inflows are delayed.
Ongoing GAAP Losses & Negative ROEDespite revenue scale, Legend remains loss‑making on a GAAP basis with materially negative returns on equity. This indicates shareholder capital is not yet producing profits, leaving the company dependent on achieving durable margin recovery to justify reinvestment and to avoid long‑term balance sheet pressure.
Collaboration Accounting & Partner DependenceA large portion of commercial economics flows through the Janssen collaboration, creating revenue recognition complexity and timing risk. Dependence on a partner for commercialization mechanics, milestones and profit sharing can obscure direct cash capture and limit Legend’s control over commercial levers and near‑term cash generation.
Legend Biotech News
LEGN FAQ
What was Legend Biotech Corporation’s price range in the past 12 months?
Legend Biotech Corporation lowest stock price was $16.24 and its highest was $45.30 in the past 12 months.
What is Legend Biotech Corporation’s market cap?
Legend Biotech Corporation’s market cap is $5.33B.
When is Legend Biotech Corporation’s upcoming earnings report date?
Legend Biotech Corporation’s upcoming earnings report date is Aug 18, 2026 which is in 51 days.
How were Legend Biotech Corporation’s earnings last quarter?
Legend Biotech Corporation released its earnings results on May 12, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of $0.012 by -$0.162.
Is Legend Biotech Corporation overvalued?
According to Wall Street analysts Legend Biotech Corporation’s price is currently Undervalued.
Does Legend Biotech Corporation pay dividends?
Legend Biotech Corporation does not currently pay dividends.
What is Legend Biotech Corporation’s EPS estimate?
Legend Biotech Corporation’s EPS estimate is 0.07.
How many shares outstanding does Legend Biotech Corporation have?
Legend Biotech Corporation has 193,439,790 shares outstanding.
What happened to Legend Biotech Corporation’s price movement after its last earnings report?
Legend Biotech Corporation reported an EPS of -$0.15 in its last earnings report, missing expectations of $0.012. Following the earnings report the stock price went up 10.477%.
Which hedge fund is a major shareholder of Legend Biotech Corporation?
Currently, no hedge funds are holding shares in LEGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Legend Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.27 (170.52% Upside)
$57.27 (170.52% Upside)
Blogger Sentiment
Bullish
LEGN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $87.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 8.1%
Last 30 Days ▲ 8.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.30%
12-Months-Change
Fundamentals
Return on Equity
-24.91%
Trailing 12-Months
Asset Growth
-1.17%
Trailing 12-Months
Company Description
Legend Biotech Corporation
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
LEGN Company Deck
LEGN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and operational performance—notably robust CARVYKTI sales growth (52% YoY), improved manufacturing metrics (99% success, 29-day turnaround), deeper earlier-line penetration (41% vs 29% YoY), a solid cash position (~$835M), and a clear path to adjusted profitability in 2026. These positives are tempered by a near-term gross margin hit (41% vs 57% prior quarter) from one-time manufacturing ramp costs, an adjusted net loss still present in Q1, event-driven uncertainty around pivotal readouts (CARTITUDE-5/6), and early-stage clinical risk for the In Vivo programs where safety/efficacy data are not yet disclosed. On balance, the highlights (strong growth, manufacturing execution, expanding pipeline, balance sheet strength, path to profitability) outweigh the lowlights, supporting a constructive view of the company's near- to mid-term outlook.View all LEGN earnings summariesLEGN Stock 12 Month Forecast
Average Price Target
$57.27
▲(170.52% Upside)
Technical Analysis
Cytokinetics
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Atrium Therapeutics, Inc.
―
Abivax SA Sponsored ADR
―
Ownership Overview
0.13% Insiders
13.30% Mutual Funds
22.44% Other Institutional Investors
61.13% Public Companies and
Individual Investors